|
Gene: SPRYD7 |
Gene summary for SPRYD7 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SPRYD7 | Gene ID | 57213 |
Gene name | SPRY domain containing 7 | |
Gene Alias | C13orf1 | |
Cytomap | 13q14.2 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q5W111 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57213 | SPRYD7 | LZE4T | Human | Esophagus | ESCC | 1.44e-16 | 4.62e-01 | 0.0811 |
57213 | SPRYD7 | LZE24T | Human | Esophagus | ESCC | 2.33e-04 | 1.70e-01 | 0.0596 |
57213 | SPRYD7 | P1T-E | Human | Esophagus | ESCC | 3.09e-04 | 2.27e-01 | 0.0875 |
57213 | SPRYD7 | P2T-E | Human | Esophagus | ESCC | 2.09e-14 | 2.74e-01 | 0.1177 |
57213 | SPRYD7 | P4T-E | Human | Esophagus | ESCC | 4.20e-09 | 1.67e-01 | 0.1323 |
57213 | SPRYD7 | P5T-E | Human | Esophagus | ESCC | 4.97e-17 | 3.64e-01 | 0.1327 |
57213 | SPRYD7 | P8T-E | Human | Esophagus | ESCC | 5.58e-11 | 2.77e-01 | 0.0889 |
57213 | SPRYD7 | P9T-E | Human | Esophagus | ESCC | 2.84e-19 | 4.37e-01 | 0.1131 |
57213 | SPRYD7 | P10T-E | Human | Esophagus | ESCC | 3.61e-19 | 2.37e-01 | 0.116 |
57213 | SPRYD7 | P11T-E | Human | Esophagus | ESCC | 4.81e-10 | 3.72e-01 | 0.1426 |
57213 | SPRYD7 | P12T-E | Human | Esophagus | ESCC | 4.30e-21 | 2.76e-01 | 0.1122 |
57213 | SPRYD7 | P15T-E | Human | Esophagus | ESCC | 8.98e-23 | 3.75e-01 | 0.1149 |
57213 | SPRYD7 | P16T-E | Human | Esophagus | ESCC | 1.27e-10 | 2.18e-01 | 0.1153 |
57213 | SPRYD7 | P17T-E | Human | Esophagus | ESCC | 9.42e-08 | 3.74e-01 | 0.1278 |
57213 | SPRYD7 | P19T-E | Human | Esophagus | ESCC | 1.42e-03 | 5.29e-01 | 0.1662 |
57213 | SPRYD7 | P20T-E | Human | Esophagus | ESCC | 5.63e-20 | 4.10e-01 | 0.1124 |
57213 | SPRYD7 | P21T-E | Human | Esophagus | ESCC | 2.99e-19 | 4.88e-01 | 0.1617 |
57213 | SPRYD7 | P22T-E | Human | Esophagus | ESCC | 6.98e-16 | 3.52e-01 | 0.1236 |
57213 | SPRYD7 | P23T-E | Human | Esophagus | ESCC | 4.36e-17 | 3.99e-01 | 0.108 |
57213 | SPRYD7 | P24T-E | Human | Esophagus | ESCC | 6.74e-16 | 3.97e-01 | 0.1287 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPRYD7 | SNV | Missense_Mutation | rs763469553 | c.284G>A | p.Arg95Gln | p.R95Q | Q5W111 | protein_coding | tolerated(0.63) | benign(0.001) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
SPRYD7 | SNV | Missense_Mutation | novel | c.11C>T | p.Ser4Leu | p.S4L | Q5W111 | protein_coding | tolerated(0.29) | benign(0) | TCGA-LD-A7W5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
SPRYD7 | SNV | Missense_Mutation | rs772902529 | c.172N>A | p.Ala58Thr | p.A58T | Q5W111 | protein_coding | tolerated(0.14) | benign(0.082) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SPRYD7 | SNV | Missense_Mutation | novel | c.23N>A | p.Cys8Tyr | p.C8Y | Q5W111 | protein_coding | deleterious(0) | benign(0.063) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SPRYD7 | SNV | Missense_Mutation | rs772902529 | c.172N>A | p.Ala58Thr | p.A58T | Q5W111 | protein_coding | tolerated(0.14) | benign(0.082) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
SPRYD7 | SNV | Missense_Mutation | novel | c.241N>A | p.Val81Ile | p.V81I | Q5W111 | protein_coding | tolerated(0.09) | possibly_damaging(0.622) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPRYD7 | SNV | Missense_Mutation | novel | c.534N>G | p.Phe178Leu | p.F178L | Q5W111 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SPRYD7 | SNV | Missense_Mutation | novel | c.112G>A | p.Asp38Asn | p.D38N | Q5W111 | protein_coding | tolerated(0.09) | benign(0.142) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPRYD7 | SNV | Missense_Mutation | novel | c.374N>C | p.Gln125Pro | p.Q125P | Q5W111 | protein_coding | deleterious(0.01) | possibly_damaging(0.506) | TCGA-EC-A24G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SPRYD7 | SNV | Missense_Mutation | c.77N>G | p.Pro26Arg | p.P26R | Q5W111 | protein_coding | deleterious(0.03) | probably_damaging(0.946) | TCGA-73-4668-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | pemetrexed | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |